Former MinuteClinic CEO appointed chair of Mednet board
MINNEAPOLIS Mednet, which specializes in Health Information Exchange applications and services, has elected former MinuteClinic CEO Michael Howe to serve as chairman of its board of directors.
"Mednet has great technology for rapidly building modern and standardized health information exchanges," stated Howe. "However, what excites me the most is Mednet’s focus on ensuring the privacy of patient information and engaging the patient in their own health care information. I want to help build a company that puts the privacy and security of patient information first. This strategic approach to information exchange is the right platform from which to engage the provider and investment community in Mednet as the secure, safe choice as we connect health care."
Howe joined MinuteClinic as CEO in June 2005. Under Howe’s leadership, the retail-based clinic operator expanded to more than 500 clinics in 27 states. In 2006, MinuteClinic was acquired by CVS Caremark. In 2007, he was appointed to the Minnesota Governor’s Healthcare Transformation Task Force. In addition to being CEO of MinuteClinic and Arby’s, Howe held several positions with Procter & Gamble and PepsiCo.
"Mr. Howe, with his extensive healthcare expertise, has embraced this opportunity to build another national healthcare success story," added Mednet CEO John Fraser. "We are very pleased to have Michael Howe as chairman of the Mednet board of directors, and look forward to his positive impact to our company, our customers and most importantly on patient care."
Study finds Victoza more effective in treating Type 2 diabetes than competitor
PRINCETON, N.J. A study published online in the journal Diabetes Care indicated that a once-daily diabetes drug made by Novo Nordisk “further improves” blood sugar control and weight loss when patients switch to it from a competitor made by Eli Lilly, Novo Nordisk announced Tuesday.
The study, conducted by the Danish drug maker, was a 26-week study in Type 2 diabetes patients taking Novo Nordisk’s Victoza (liraglutide) or Lilly’s twice-daily Byetta (exenatide). The drugs are the only glucagon-like peptide-1, or GLP-1 agonists available on the market.
“Clinical benefits were seen in patients who switched from exenatide to Victoza,” University of North Carolina School of Medicine Diabetes Care Center director and study investigator John Buse said. “The significant improvements in blood sugar lowering and fasting glucose confirm the original findings of the trial regarding the efficacy of Victoza.”
Hospira completes Orchid acquisition
LAKE FOREST, Ill. Hospira has completed its $400 million acquisition of the generic injectables business of Orchid Chemicals & Pharmaceuticals, the generic drug maker announced Tuesday.
“We are excited to acquire new capabilities that will create opportunities for commercial growth, position us strongly in a key antibiotics product area, expand our global footprint and enhance our ability to provide lower-cost, high-quality products to patients,” Hospira COO Terry Kearney said. “We’re also excited to welcome a talented base of 450 employees, including newly appointed managing director [for] Hospira India, Dr. C.B. Rao, who joins us with a wealth of diversified industrial and management experience, and will provide continuity of leadership for the Orchid team joining Hospira.”
The acquisition, announced in February, includes Orchid’s beta-lactam antibiotic formuatlions manufacturing complex — comprising penicillin, cephalosporin and carbapenem facilities — and a pharmaceutical research and development facility in Irungattukottai, Chennai.